Lyra Therapeutics (NASDAQ:LYRA) & CVR Medical (OTCMKTS:CRRVF) Critical Comparison

Lyra Therapeutics (NASDAQ:LYRA) and CVR Medical (OTCMKTS:CRRVF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.

Institutional and Insider Ownership

95.6% of Lyra Therapeutics shares are owned by institutional investors. 4.7% of Lyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Lyra Therapeutics and CVR Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,570.88%	-102.22%	-57.77%
CVR Medical	N/A	N/A	N/A

Valuation & Earnings

This table compares Lyra Therapeutics and CVR Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$1.82 million	9.80	-$62.68 million	($1.58)	-0.17
CVR Medical	N/A	N/A	-$1.82 million	N/A	N/A

CVR Medical has lower revenue, but higher earnings than Lyra Therapeutics.

Analyst Ratings

This is a breakdown of current ratings and price targets for Lyra Therapeutics and CVR Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1	4	1	0	2.00
CVR Medical	0	0	0	0	N/A

Lyra Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 1,550.77%.

About Lyra Therapeutics

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

About CVR Medical

CVR Medical Corp., a healthcare company, engages in the research and development of subsonic, infrasonic, and low frequency sound wave analysis technology for the healthcare sector. The company provides carotid stenotic scan device, a diagnostic tool to detect and measure carotid arterial stenosis. It offers its products for patients, payors, and healthcare providers. CVR Medical Corp. was incorporated in 1980 and is headquartered in North Vancouver, Canada.